On September 20, 2022 Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, reported that it will present the latest developments on delivery of novel RNAi therapies for cancer, and its GalAhead platform and programs, at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference (Press release, Sirnaomics, SEP 20, 2022, View Source [SID1234619710]). The conference will take place on September 21 and 22, 2022 with workshops on September 20, 2022 at Copthorne Tara Hotel, London, UK.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Presentation Title: Delivery of Novel siRNA Constructs for Treating Cancer
Presenter: Dr. David Evans, Chief Scientific Officer, Sirnaomics
Time/Date: 15:20 GMT on Wednesday, September 21, 2022
Presentation Topics:
Creating novel siRNA constructs for cancer treatment
Introduction to Sirnaomics’ polypeptide nanoparticle delivery system (PNP-IT)
Introduction to STP705, Sirnaomics’ lead oncology siRNA therapeutic targeting TGF-β1/COX-2
Discussion of novel siRNA therapeutics targeting other oncology indications

Presentation Title: GalAhead Therapeutic Platform and Programs
Presenter: Dr. Jack Wei, Senior Director, Sirnaomics
Time/Date: 16:30 GMT on Thursday, September 22, 2022
Presentation Topics:
Introduction to GalAhead, Sirnaomics’ GalNAc-RNAi therapeutic platform
Miniaturized RNAi (mxRNA) as a key technological component of the platform
Validation of technology in vivo and in vitro
Progress report on GalAhead-based programs